BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16178783)

  • 1. Thymidylate synthase structure, function and implication in drug discovery.
    Costi MP; Ferrari S; Venturelli A; Calò S; Tondi D; Barlocco D
    Curr Med Chem; 2005; 12(19):2241-58. PubMed ID: 16178783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-based thymidylate synthase inhibitors as anticancer drugs.
    Jackman AL; Calvert AH
    Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
    Van Triest B; Peters GJ
    Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
    Van Triest B; Pinedo HM; Giaccone G; Peters GJ
    Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
    Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
    Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
    Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
    Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chemical strategies for thymidylate synthase inhibition.
    Gmeiner WH
    Curr Med Chem; 2005; 12(2):191-202. PubMed ID: 15638735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
    Takemura Y; Jackman AL
    Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future potential of thymidylate synthase inhibitors in cancer therapy.
    Lehman NL
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1775-87. PubMed ID: 12457437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
    Brandt DS; Chu E
    Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase inhibition: a structure-based rationale for drug design.
    Costi MP
    Med Res Rev; 1998 Jan; 18(1):21-42. PubMed ID: 9436180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX.
    Hunter JH; Gujjar R; Pang CK; Rathod PK
    PLoS One; 2008 May; 3(5):e2237. PubMed ID: 18493582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.